Trials / Completed
CompletedNCT00322764
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Repligen Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Uridine |
Timeline
- Start date
- 2006-03-01
- First posted
- 2006-05-08
- Last updated
- 2007-11-09
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00322764. Inclusion in this directory is not an endorsement.